Cost-effectiveness of polysaccharide pneumococcal vaccination in people aged 65 and above in Poland

References

• Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:RR-8 1 - 24; PMID: 9132580
   PubMedGoogle Scholar
• Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, et al. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine 2006; 24:5690 - 9; http://dx.doi.org/10.1016/j.vaccine.2006.04.042; PMID: 16735083
   PubMed Web of Science ®Google Scholar
• 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008; 83:373 - 84; PMID: 18927997
   PubMedGoogle Scholar
• Kyaw MH, Rose CE Jr., Fry AM, Singleton JA, Moore Z, Zell ER, et al, Active Bacterial Core Surveillance Program of the Emerging Infections Program Network. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005; 192:377 - 86; http://dx.doi.org/10.1086/431521; PMID: 15995950
   PubMed Web of Science ®Google Scholar
• Pebody RG, Hellenbrand W, D’Ancona F, Ruutu P, European Union funded Pnc-EURO contributing group. Pneumococcal disease surveillance in Europe. Euro Surveill 2006; 11:171 - 8; PMID: 17075159
   PubMedGoogle Scholar
• Melegaro A, Edmunds WJ. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. Eur J Epidemiol 2004; 19:353 - 63; http://dx.doi.org/10.1023/B:EJEP.0000024701.94769.98; PMID: 15180106
   PubMed Web of Science ®Google Scholar
• Polish Central Statistical Office. . see: http://www.stat.gov.pl/gus/5840_655_ENG_HTML.htm
   Google Scholar
• ECDC surveillance report 2009; antimicrobial resistance surveillance in Europe 2009, http://www.ecdc.europa.eu/en/publications/Publications/1011_SUR_annual_EARS_Net_2009.pdf
   Google Scholar
• Fedson DS, Musher DM. Pneumococcal polysaccharide vaccine. In: Vaccines (Plotkin,SA, Orenstein,WA, eds), 4th edn. 2004: 543.
   Google Scholar
• Jahnz-Rózyk K. . [Health economic impact of viral respiratory infections and pneumonia diseases on the elderly population in Poland]. Pol Merkuriusz Lek 2010; 29:37 - 40
   PubMedGoogle Scholar
• Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Intern Med 2003; 138:960 - 8; PMID: 12809452
   PubMed Web of Science ®Google Scholar
• Ament A, Baltussen R, Duru G, Rigaud-Bully C, de Graeve D, Ortqvist A, et al. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin Infect Dis 2000; 31:444 - 50; http://dx.doi.org/10.1086/313977; PMID: 10987703
   PubMed Web of Science ®Google Scholar
• Akin L, Kaya M, Altinel S, Durand L. Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey. Hum Vaccin 2011; 7:441 - 50; http://dx.doi.org/10.4161/hv.7.4.14188; PMID: 21441776
   PubMed Web of Science ®Google Scholar
• U.S. Census Bureau. International Data Base (IDB), http://www.census.gov/ipc/www/idb/ country.php, accessed in March 2011.
   Google Scholar
• WHO. CHoosing Interventions that are Cost Effective http://www.who.int/choice/costs/CER_levels/en/index.html
   Google Scholar
• WHO. Social indicators. http://unstats.un.org/unsd/demographic/products/socind/inc-eco.htm
   Google Scholar
• XE. http://www.xe.com/ict/ 19th July 2011
   Google Scholar
• de Andres AL, Garrido PC, Hernández-Barrera V, Del Pozo SV, de Miguel AG, Jiménez-García R. Influenza vaccination among the elderly Spanish population: trend from 1993 to 2003 and vaccination-related factors. Eur J Public Health 2007; 17:272 - 7; http://dx.doi.org/10.1093/eurpub/ckl242; PMID: 17071634
   PubMed Web of Science ®Google Scholar
• Fleming DM, Elliot AJ. Estimating the risk population in relation to influenza vaccination policy. Vaccine 2006; 24:4378 - 85; http://dx.doi.org/10.1016/j.vaccine.2006.02.053; PMID: 16574281
   PubMed Web of Science ®Google Scholar
• Mullooly JP, Bennett MD, Hornbrook MC, Barker WH, Williams WW, Patriarca PA, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121:947 - 52; PMID: 7978721
   PubMed Web of Science ®Google Scholar
• Ryan J, Zoellner Y, Gradl B, Palache B, Medema J. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 2006; 24:6812 - 22; http://dx.doi.org/10.1016/j.vaccine.2006.07.042; PMID: 17034909
   PubMed Web of Science ®Google Scholar
• Rychlik R, Heinen-Kammerer T, Rusche H, Piercy J, Scuffham P, Zöllner Y. [Cost-effectiveness of prophylaxis and treatment of influenza]. Dtsch Med Wochenschr 2003; 128:2267 - 70; PMID: 14574642
   PubMed Web of Science ®Google Scholar
• Evers SM, Ament AJ, Colombo GL, Konradsen HB, Reinert RR, Sauerland D, et al. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 2007; 26:531 - 40; http://dx.doi.org/10.1007/s10096-007-0327-z; PMID: 17570001
   PubMed Web of Science ®Google Scholar
• Weaver M, Krieger J, Castorina J, Walls M, Ciske S. Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines. Arch Intern Med 2001; 161:111 - 20; http://dx.doi.org/10.1001/archinte.161.1.111; PMID: 11146707
   PubMed Web of Science ®Google Scholar
• Baltussen R, Ament A, Leidl RM, et al. Cost-effectiveness of vaccination against pneumococcal pneumonia in the Netherlands. Eur J Public Health 1997; 7:153 - 61; http://dx.doi.org/10.1093/eurpub/7.2.153
   Web of Science ®Google Scholar
• Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, et al. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines 2011; 10:1143 - 67; http://dx.doi.org/10.1586/erv.11.99; PMID: 21810065
   PubMed Web of Science ®Google Scholar
• Grijalva CG, Griffin MR. Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA. Expert Rev Vaccines 2008; 7:83 - 95; http://dx.doi.org/10.1586/14760584.7.1.83; PMID: 18251696
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention –CDC- 2007 National Immunization Survey
   Google Scholar
• Reinert RR, Haupts S, van der Linden M, Heeg C, Cil MY, Al-Lahham A, et al. Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003. Clin Microbiol Infect 2005; 11:985 - 91; http://dx.doi.org/10.1111/j.1469-0691.2005.01282.x; PMID: 16307552
   PubMed Web of Science ®Google Scholar
• Pneumococcal Vaccines Workgroup ACIP. , 25.06.2008
   Google Scholar
• Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009; 49:205 - 12; http://dx.doi.org/10.1086/599827; PMID: 19508165
   PubMed Web of Science ®Google Scholar
• Vestrheim DF, Høiby EA, Bergsaker MR, Rønning K, Aaberge IS, Caugant DA. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine 2010; 28:2214 - 21; http://dx.doi.org/10.1016/j.vaccine.2009.12.054; PMID: 20056192
   PubMed Web of Science ®Google Scholar
• Ardanuy C, Tubau F, Pallares R, Calatayud L, Domínguez MA, Rolo D, et al. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis 2009; 48:57 - 64; http://dx.doi.org/10.1086/594125; PMID: 19035779
   PubMed Web of Science ®Google Scholar
• Rodenburg GD, de Greeff SC, Jansen AG, de Melker HE, Schouls LM, Hak E, et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010; 16:816 - 23; http://dx.doi.org/10.3201/eid1605.091223; PMID: 20409372
   PubMed Web of Science ®Google Scholar
• Smith KJ, Lee BY, Nowalk MP, Raymund M, Zimmerman RK. Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Vaccine 2010; 28:7620 - 5; http://dx.doi.org/10.1016/j.vaccine.2010.09.053; PMID: 20887828
   PubMed Web of Science ®Google Scholar
• Redekop WK, Orlewska E, Maciejewski P, Rutten FF, Niessen LW. Costs and effects of secondary prevention with perindopril in stable coronary heart disease in Poland: an analysis of the EUROPA study including 1251 Polish patients. Pharmacoeconomics 2008; 26:861 - 77; http://dx.doi.org/10.2165/00019053-200826100-00006; PMID: 18793033
   PubMed Web of Science ®Google Scholar
• Simon K, Gladysz A, Rotter K, et al. Cost effectiveness of replacing recombinated interferon alpha-2b with its pegylated form in combination with ribavirin for the therapy of chronic HCV infection in Poland. Advances in Clinical and Experimental Medicine 2006; 15:453 - 62
   Google Scholar
• Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004; 22:3214 - 24; http://dx.doi.org/10.1016/j.vaccine.2003.08.050; PMID: 15297076
   PubMed Web of Science ®Google Scholar
• Orlewska, Ewa and Mierzejewski, Piotr. Polish guidelines for conducting pharmacoeconomic evaluations. 1-15. 2009.
   Google Scholar
• U.S. Census Bureau. International Data Base (IDB), http://www.census.gov/ipc/www/idb/ country.php, accessed in March 2011.
   Google Scholar
• Weinstein MC, O’Brien B, Hornberger J et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.
   Google Scholar
• 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008; 83:373 - 84; PMID: 18927997
   PubMedGoogle Scholar
• Fedson DS. Pneumococcal vaccination for older adults: the first 20 years. Drugs Aging 1999; 15:Suppl 1 21 - 30; http://dx.doi.org/10.2165/00002512-199915001-00003; PMID: 10690792
   PubMed Web of Science ®Google Scholar
• Ament A, Baltussen R. Duru G and al. Cost-Effectiveness of Pneumococcal Vaccination of Older People : A Study in 5 Western European Countries. Clin Infect Dis 2000; 33:444 - 50; http://dx.doi.org/10.1086/313977
   Web of Science ®Google Scholar
• Fantin B, Aubert JP, Unger P, Lecoeur H, Carbon C. Clinical evaluation of the management of community-acquired pneumonia by general practitioners in France. Chest 2001; 120:185 - 92; http://dx.doi.org/10.1378/chest.120.1.185; PMID: 11451836
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, Raga-Luria X, Gomez-Bertomeu F, EPIVAC Study Group. Epidemiology of community-acquired pneumonia in older adults: a population-based study. Respir Med 2009; 103:309 - 16; http://dx.doi.org/10.1016/j.rmed.2008.08.006; PMID: 18804355
   PubMed Web of Science ®Google Scholar
• Vila-Corcoles A, Salsench E, Rodriguez-Blanco T, Ochoa-Gondar O, de Diego C, Valdivieso A, et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine 2009; 27:1504 - 10; http://dx.doi.org/10.1016/j.vaccine.2009.01.013; PMID: 19171174
   PubMed Web of Science ®Google Scholar
• Bohr V, Rasmussen N, Hansen B, Gade A, Kjersem H, Johnsen N, et al. Pneumococcal meningitis: an evaluation of prognostic factors in 164 cases based on mortality and on a study of lasting sequelae. J Infect 1985; 10:143 - 57; http://dx.doi.org/10.1016/S0163-4453(85)91585-3; PMID: 4008963
   PubMed Web of Science ®Google Scholar
• Mooney JD, Weir A, McMenamin J, Ritchie LD, Macfarlane TV, Simpson CR, et al. The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004. BMC Infect Dis 2008; 8:53; http://dx.doi.org/10.1186/1471-2334-8-53; PMID: 18433473
   PubMed Web of Science ®Google Scholar
• Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993; 270:1826 - 31; http://dx.doi.org/10.1001/jama.1993.03510150060030; PMID: 8411526
   PubMed Web of Science ®Google Scholar
• Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009; 180:48 - 58; http://dx.doi.org/10.1503/cmaj.080734; PMID: 19124790
   PubMed Web of Science ®Google Scholar
• Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008; CD000422; PMID: 18253977
   PubMedGoogle Scholar
• Middleton DB, Lin CJ, Smith KJ, Zimmerman RK, Nowalk MP, Roberts MS, et al. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients. Infect Control Hosp Epidemiol 2008; 29:385 - 94; http://dx.doi.org/10.1086/587155; PMID: 18521990
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325:1453 - 60; http://dx.doi.org/10.1056/NEJM199111213252101; PMID: 1944423
   PubMed Web of Science ®Google Scholar
• Demographic Yearbook of Poland 2008. 2008. Polish Central Statistic Office.
   Google Scholar
• Szende A, Németh R. [Health-related quality of life of the Hungarian population]. Orv Hetil 2003; 144:1667 - 74; PMID: 14528840
   PubMedGoogle Scholar
• Dominguez A, Salleras L, Fedson DS, Izquierdo C, Ruiz L, Ciruela P, et al. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study. Clin Infect Dis 2005; 40:1250 - 7; http://dx.doi.org/10.1086/429236; PMID: 15825026
   PubMed Web of Science ®Google Scholar
• Vila-Córcoles A, Ochoa-Gondar O, Hospital I, Ansa X, Vilanova A, Rodríguez T, et al, EVAN Study Group. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006; 43:860 - 8; http://dx.doi.org/10.1086/507340; PMID: 16941367
   PubMed Web of Science ®Google Scholar
• De Graeve D, Lombaert G, Goossens H. Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium. Pharmacoeconomics 2000; 17:591 - 601; http://dx.doi.org/10.2165/00019053-200017060-00005; PMID: 10977396
   PubMed Web of Science ®Google Scholar
• Sisk JE, Moskowitz AJ, Whang W, Lin JD, Fedson DS, McBean AM, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997; 278:1333 - 9; http://dx.doi.org/10.1001/jama.1997.03550160053038; PMID: 9343464
   PubMed Web of Science ®Google Scholar
• Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, et al, Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 2001; 285:1729 - 35; http://dx.doi.org/10.1001/jama.285.13.1729; PMID: 11277827
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52:229 - 46; http://dx.doi.org/10.1093/jac/dkg321; PMID: 12865398
   PubMed Web of Science ®Google Scholar
• Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur J Health Econ 2008; 9:7 - 15; http://dx.doi.org/10.1007/s10198-006-0013-6; PMID: 17333089
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, et al, Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348:1747 - 55; http://dx.doi.org/10.1056/NEJMoa022678; PMID: 12724480
   PubMed Web of Science ®Google Scholar
• Smith KJ, Roberts MS. Cost-effectiveness of newer treatment strategies for influenza. Am J Med 2002; 113:300 - 7; http://dx.doi.org/10.1016/S0002-9343(02)01222-6; PMID: 12361816
   PubMed Web of Science ®Google Scholar
• Smith KJ, Zimmerman RK, Lin CJ, Nowalk MP, Ko FS, McEllistrem MC, et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine 2008; 26:1420 - 31; http://dx.doi.org/10.1016/j.vaccine.2008.01.007; PMID: 18272262
   PubMed Web of Science ®Google Scholar
• De Wals P, Petit G, Erickson LJ, Guay M, Tam T, Law B, et al. Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada. Vaccine 2003; 21:3757 - 64; http://dx.doi.org/10.1016/S0264-410X(03)00361-X; PMID: 12922109
   PubMed Web of Science ®Google Scholar